AZNCF Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of --. AstraZeneca PLC's return on equity of 22.01% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.

AstraZeneca PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 3394.13%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than AstraZeneca PLC, analysts believe Biodexa Pharmaceuticals Plc is more attractive than AstraZeneca PLC.

AstraZeneca PLC has a beta of 0.350, which suggesting that the stock is 65.03% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.

AstraZeneca PLC has a quarterly dividend of $1.02 per share corresponding to a yield of 1.72%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 69.15% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

AstraZeneca PLC quarterly revenues are $15.2B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. AstraZeneca PLC's net income of $2.5B is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.43x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.92x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

GSK Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 25.09%. AstraZeneca PLC's return on equity of 22.01% beat GSK Plc's return on equity of 42.84%.

AstraZeneca PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand GSK Plc has an analysts' consensus of $49.35 which suggests that it could grow by 1.6%. Given that GSK Plc has higher upside potential than AstraZeneca PLC, analysts believe GSK Plc is more attractive than AstraZeneca PLC.

AstraZeneca PLC has a beta of 0.350, which suggesting that the stock is 65.03% less volatile than S&P 500. In comparison GSK Plc has a beta of 0.470, suggesting its less volatile than the S&P 500 by 52.951%.

AstraZeneca PLC has a quarterly dividend of $1.02 per share corresponding to a yield of 1.72%. GSK Plc offers a yield of 3.45% to investors and pays a quarterly dividend of $0.42 per share. AstraZeneca PLC pays 69.15% of its earnings as a dividend. GSK Plc pays out 94.89% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

AstraZeneca PLC quarterly revenues are $15.2B, which are larger than GSK Plc quarterly revenues of $11.5B. AstraZeneca PLC's net income of $2.5B is lower than GSK Plc's net income of $2.9B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.43x while GSK Plc's PE ratio is 13.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.92x versus 2.38x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.

NuCana Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of --. AstraZeneca PLC's return on equity of 22.01% beat NuCana Plc's return on equity of -286.82%.

AstraZeneca PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 469425.96%. Given that NuCana Plc has higher upside potential than AstraZeneca PLC, analysts believe NuCana Plc is more attractive than AstraZeneca PLC.

AstraZeneca PLC has a beta of 0.350, which suggesting that the stock is 65.03% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.

AstraZeneca PLC has a quarterly dividend of $1.02 per share corresponding to a yield of 1.72%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 69.15% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

AstraZeneca PLC quarterly revenues are $15.2B, which are larger than NuCana Plc quarterly revenues of --. AstraZeneca PLC's net income of $2.5B is higher than NuCana Plc's net income of -$378.9K. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.43x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.92x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.